Extraosseous plasmacytoma

ICD-O-1 Morphology
Effective 1978 - 1991
ICD-O-2 Morphology
Effective 1992 - 2000
ICD-O-3 Morphology
Effective 2001 and later
for cases diagnosed 1978 and later
Primary Site(s)
See Module 7
Primary site cannot be bone (C400-419). Most common sites of involvement: upper respiratory tract (80%), oropharynx, nasopharynx, sinuses, larynx, gastrointestinal tract, lymph nodes, bladder, CNS, breast, thyroid, testis, parotid, and skin

Help me code for diagnosis year :

6 - B-cell
Module Rule
Module 2: PH2
Alternate Names
Plasmacytoma refers to a malignant monoclonal plasma cell tumor growing within soft tissue.

Clonal proliferation of plasma cells cytologically and immunophenotypically identical to those of plasma cell myeloma but forming tumors at extraosseous and extramedullary sites.
Abstractor Notes
Do not code primary site to C40._ or C41._. These category codes should only be used with histology 9731/3.

These plasmacytomas are localized plasma cell neoplasms that arise in tissues other than bone. About 15% of upper respiratory plasmacytomas spread to the cervical lymph nodes.

Radiology and bone marrow examination show no evidence of involvement.

Do not code plasma cell myeloma/multiple myeloma (9732/3) just because there are multiple extraosseous plasmacytomas.

FISH and immunophenotyping help to differentiate these lesions from MALT lymphoma.
Definitive Diagnostic Methods
Genetic testing
Histologic confirmation
Genetics Data
Ig clonal rearrangements, complex karyotypes with multiple chromosomal gains/losses; also translocations, deletions, mutations
Small M protein, most commonly IgA
Transformations to
Transformations from
Same Primaries
There are no known same primaries
Corresponding ICD-9 Codes
203.8 Other immunoproliferative neoplasms
Corresponding ICD-10 Codes
C90.2 Plasmacytoma, extramedullary
Corresponding ICD-10-CM Codes (effective October 1, 2015 U.S. only)
C90.2 Extramedullary plasmacytoma
Signs and Symptoms
Nasal obstruction
Presence of M-protein, most commonly IgA (~20% of patients)
Diagnostic Exams
Complete blood count (CBC)
Cytogenetic analysis
MRI (magnetic resonance imaging)
Skeletal survey
Tissue biopsy
Twenty-four-hour urine test
Recurrence and Metastases
Regional recurrences occur in ~25% of patients
Occasionally metastasis to distant extraosseous sites
Progression to plasma cell myeloma occurs in ~15% of cases
Epidemiology and Mortality
Age: 55 years median age
Incidence: 3-5% of plasma cell neoplasms
Sex: male predominance
Survival: ~70% of patients remain disease free at 10 years